STANKOVICH THOMAS 4
4 · ReShape Lifesciences Inc. · Filed Nov 8, 2023
Insider Transaction Report
Form 4
STANKOVICH THOMAS
Chief Financial Officer
Transactions
- Sale
Common Stock, $0.001 par value per share
2023-08-04$1.43/sh−108$154→ 23,276 total - Sale
Common Stock, $0.001 par value per share
2023-09-01$0.89/sh−118$105→ 23,119 total - Sale
Common Stock, $0.001 par value per share
2023-10-25$0.27/sh−131$35→ 22,949 total - Sale
Common Stock, $0.001 par value per share
2023-08-24$1.42/sh−39$55→ 23,237 total - Sale
Common Stock, $0.001 par value per share
2023-10-11$0.93/sh−39$36→ 23,080 total
Footnotes (1)
- [F1]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.